Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLunglife Ai Regulatory News (LLAI)

Share Price Information for Lunglife Ai (LLAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -0.40 (-1.91%)
Spread: 1.00 (5.00%)
Open: 20.90
High: 20.90
Low: 20.50
Prev. Close: 20.90
LLAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Special Meeting

21 Mar 2024 14:05

RNS Number : 8390H
LungLife AI, INC
21 March 2024
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

 

21 March 2024

LungLife AI, Inc.

 

(the "Company" or "LungLife")

 

Result of Special Meeting

 

LungLife AI, Inc. (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that at the Special Meeting held earlier today, all resolutions proposed were duly passed by shareholders. A summary of the voting results is shown below:

 

For

Against

Withheld

Total Votes Cast

% Voting For*

Resolution 1

19,992,507

20,006

0

20,012,513

78.45%

Resolution 2

19,992,507

20,006

0

20,012,513

78.45%

Resolution 3

19,992,507

20,006

0

20,012,513

78.45%

Resolution 4

19,992,507

20,006

0

20,012,513

78.45%

* This column represents the number of votes that were cast for the resolutions as a percentage of the total issued and outstanding shares of the Company as at the record date for the meeting.

Accordingly, subject to admission of the New Shares to trading on AIM, the Company has raised a total of £1.8 million (before expenses) via the Placing and Subscription through the issue and allotment of 5,172,621 new Common Shares. An application has been made for the New Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 22 March 2024.

Unless otherwise defined in this announcement, capitalised terms used in this announcement shall have the same meanings as defined in the Company's announcement of 4 March 2024.

 

Enquiries:

 

 

LungLife AI, Inc.

www.lunglifeai.com

Paul Pagano, CEO 

Via Walbrook PR

David Anderson, CFO

 

 

 

Investec Bank plc (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7597 5970

Virginia Bull / Cameron MacRitchie / Lydia Zychowska

Goodbody Stockbrokers UC (Joint Broker)

Tom Nicholson / Cameron Duncan / William Hall

 

Tel: +44 (0)20 3841 6202

Walbrook PR Limited

 Tel: +44 (0)20 7933 8780

Paul McManus / Alice Woodings / Phillip Marriage

or LungLifeAI@walbrookpr.com

 

 

About LungLife AI Inc

 

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com.

 

 

IMPORTANT NOTICES

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION, FORWARDING OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in or into the United States, or to or for the account or benefit of US persons (as defined in Regulation S under the Securities Act ("Regulation S")), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any State or any other jurisdiction of the United States.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMUARSRSSUOUAR
12
Date   Source Headline
15th May 20247:00 amRNSBlock Listing Six Monthly Return
2nd May 20244:04 pmRNSHolding(s) in Company
25th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
17th Apr 20247:00 amRNSPresentation at NCI's EDRN Meeting
4th Apr 20247:00 amRNSPreliminary Audited Results
27th Mar 20247:00 amRNSNotice of Results
26th Mar 20241:49 pmRNSHolding(s) in Company
25th Mar 202410:33 amRNSHolding(s) in Company
22nd Mar 20249:39 amRNSAdmission of New Shares & PDMR Dealing
22nd Mar 20248:21 amRNSAdmission of New Shares & PDMR Dealing
21st Mar 20242:05 pmRNSResult of Special Meeting
6th Mar 20245:35 pmRNSPosting of Circular and Notice of Special Meeting
5th Mar 20247:00 amRNSResults of Placing and Subscription
4th Mar 20244:56 pmRNSProposed equity raise of approximately £1.8m
2nd Jan 20247:00 amRNSSuccessful validation study results for LungLB®
15th Nov 20237:00 amRNSBlock Listing Six Monthly Return
28th Sep 20237:00 amRNSClinical validation study update
14th Aug 20231:32 pmRNSDirector share purchases
8th Aug 20237:00 amRNSHalf-year Report
3rd Aug 20237:00 amRNSNotice of Results
6th Jun 20237:00 amRNSLungLB® study published in peer-reviewed journal
23rd May 20237:00 amRNSEnrolment completed for LungLB® validation study
15th May 20237:00 amRNSBlock Listing Six Monthly Return
4th May 20235:49 pmRNSResult of AGM
2nd May 20237:00 amRNSConfirmation of AGM
6th Apr 20233:50 pmRNSPublication of Annual Report & Notice of AGM
14th Mar 20237:00 amRNSAppointment of Joint Broker
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
7th Mar 20237:00 amRNSHealth economics publication
27th Feb 20237:00 amRNSData on cost-effectiveness of LungLB®
20th Feb 20237:00 amRNSPreliminary results for year ended 31 Dec 2022
8th Feb 20237:00 amRNSNotice of Results
7th Dec 20222:37 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSFinal Pricing Determination
30th Nov 20227:00 amRNSTotal Voting Rights
15th Nov 20227:00 amRNSBlock Listing Six Monthly Return
3rd Nov 20227:00 amRNSDirector share purchases
17th Oct 20227:00 amRNSParticipation in National Cancer Institute’s EDRN
26th Sep 20227:00 amRNSHalf-year Report
9th Sep 20227:00 amRNSNotice of Results
2nd Sep 20227:00 amRNSNew York State approval for commercial testing
16th May 20227:00 amRNSBlock Listing Six Monthly Return
11th May 20223:17 pmRNSResult of AGM
8th Apr 20227:00 amRNSPublication of AR and Accounts & Notice of AGM
28th Mar 20227:00 amRNSPreliminary Results
17th Mar 20227:00 amRNSVA sites in validation study; SAB appointment
2nd Feb 20227:00 amRNSFirst patient enrolment for LungLB® study
4th Jan 20227:00 amRNSCPT® Code granted by American Medical Association
19th Nov 20217:00 amRNSLungLife AI Laboratory achieves CAP accreditation
10th Nov 20217:00 amRNSBlock Listing Application
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.